Raymond James & Associates Vaxcyte, Inc. Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
A detailed history of Raymond James & Associates transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 69,437 shares of PCVX stock, worth $7.85 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,437
Previous 66,332
4.68%
Holding current value
$7.85 Million
Previous $4.53 Million
15.71%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PCVX
# of Institutions
286Shares Held
110MCall Options Held
248KPut Options Held
109K-
Black Rock Inc. New York, NY9.94MShares$1.12 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.8MShares$1.11 Billion0.01% of portfolio
-
Janus Henderson Group PLC London, X08.87MShares$1 Billion0.37% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.2MShares$928 Million9.34% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$519 Million0.06% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $6.71B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...